Friday, 28 May 2010

dienogest and estradiol


Generic Name: dienogest and estradiol (dye EN oh jest and ESS tra DYE ole)

Brand Names: Natazia


What is dienogest and estradiol?

Dienogest and estradiol is a combination of female hormones that prevent ovulation (the release of an egg from an ovary). This medication also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.


Dienogest and estradiol is used as contraception to prevent pregnancy.


Dienogest and estradiol may also be used for purposes not listed in this medication guide.


What is the most important information I should know about dienogest and estradiol?


Smoking can increase your risk of blood clots, stroke, or heart attack caused by birth control pills, especially if you are older than 35. This medication can harm an unborn baby or cause birth defects. Do not use dienogest and estradiol if you are pregnant. Do not use this medication if you have a history of heart attack or stroke, a history of blood clot or coronary artery disease, circulation problems (especially if caused by diabetes), a blood clotting disorder, breast or uterine cancer, abnormal vaginal bleeding, eye problems or kidney problems caused by diabetes, liver disease or liver cancer, uncontrolled high blood pressure, severe migraine headaches, a heart valve or heart rhythm disorder, or if you smoke and you are over 35 years old.

Some drugs can make birth control pills less effective, which may result in pregnancy. Tell your doctor about all medications you use.


What should I discuss with my healthcare provider before using dienogest and estradiol?


This medication can harm an unborn baby or cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you become pregnant, or if you miss two menstrual periods in a row. If you have recently had a baby, wait at least 4 weeks before taking birth control pills. Do not use this medication if you are allergic to dienogest or estradiol, or if you have:

  • a history of heart attack, stroke, blood clot, or coronary artery disease;




  • a blood-clotting disorder, untreated or uncontrolled high blood pressure;




  • a hormone related cancer such as breast or uterine cancer;




  • abnormal vaginal bleeding;




  • problems with your eyes, kidneys, or circulation caused by diabetes;




  • liver disease or liver cancer;




  • severe migraine headaches;




  • a heart valve or heart rhythm disorder; or




  • if you smoke and you are over 35 years old.



To make sure you can safely take this medicine, tell your doctor if you have any of these other conditions:



  • high blood pressure, heart disease, congestive heart failure, high cholesterol or triglycerides;




  • a history of depression;




  • diabetes;




  • underactive thyroid; or




  • a history of jaundice caused by birth control pills.




The hormones in this medication can pass into breast milk and may harm a nursing baby. This medication may also slow breast milk production. Do not use if you are breast feeding a baby.

How should I take dienogest and estradiol?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Take your first pill on the first day of your period or on the first Sunday after your period begins. Follow the directions on your prescription label. The 28 day birth control pack contains five different colors of pills. Take one pill each day in the exact order directed on the blister pack.


Take one pill every day, no more than 24 hours apart. When the pills run out, start a new pack the following day. Get your prescription refilled before you run out of pills completely.


You may need to use back up birth control, such as condoms or a spermicide, when you first start using this medication. Follow your doctor's instructions. Do not take two different kinds of birth control pills at the same time.

If you are switching to this medication from another birth control pill, start taking dienogest and estradiol on the first day of your withdrawal bleeding and stop taking the other birth control pills. If you were taking progestin only pills before, start taking dienogest and estradiol on the day you would have taken your next pill.


If you are switching from a birth control implant, intrauterine device (IUD), vaginal ring, or skin patch, start taking dienogest and estradiol on the day the other birth control device is removed.


If you are switching from a birth control injection, start taking dienogest and estradiol on the day you would have received your next scheduled injection.


You may have breakthrough bleeding. Tell your doctor if this bleeding continues or is very heavy.


Use a back up birth control if you are sick with severe vomiting or diarrhea. Vomiting within 4 hours after your dose is the same as missing a pill.


If you need surgery or medical tests or if you will be on bed rest, you may need to stop using this medication for a short time. Any doctor or surgeon who treats you should know that you are using birth control pills. Store at room temperature away from moisture and heat.

See also: Dienogest and estradiol dosage (in more detail)

What happens if I miss a dose?


If you are less than 12 hours late in taking your pill, take the missed dose as soon as you remember. Take the next pill at the usual time, then take one pill per day in the order directed on the pack. Missing a pill by more than 12 hours increases your risk of becoming pregnant.


If you miss one pill:



  • During Days 1 through 17, take the missed pill as soon as you remember, then take your next pill at the usual time. Use back-up birth control for at least 9 days.




  • During Days 18 through 24, throw out the pack and start a new one the same day. Take the Day 1 pill from the new pack and then take one pill per day in the order directed on the pack. Use back-up birth control for at least 9 days.




  • During Days 25 through 28, take the missed pill as soon as you remember, then take your next pill at the usual time. You do not need back-up birth control if you miss one pill during Days 25 through 28.



If you miss two pills:



  • During Days 1 through 16, skip the missed pills and start with the pill that corresponds to the day you remember you missed your doses. Then take one pill per day in the order directed on the pack. Use your back up birth control for at least 9 days.




  • During Days 17 through 24, throw out the rest of the pack and start a new on the same day. Take the Day 3 pill from the new pack and then take one pill per day in the order directed on the pack. Use your back up birth control for at least 9 days.




  • During Days 25 through 28, throw out the rest of the pack. Start a new pack on the same day or on the day you would normally start a new pack. Take one pill per day in the order directed on the pack. No back up birth control is needed.




Your risk of getting pregnant will increase with the number of pills you miss. If you miss a period for two months in a row, call your doctor because you might be pregnant. Use back-up birth control if you are not sure how many pills you have missed.

What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Overdose symptoms may include nausea, vomiting, or vaginal bleeding.

What should I avoid while using dienogest and estradiol?


Do not smoke while using this medication, especially if you are older than 35. Smoking can increase your risk of blood clots, stroke, or heart attack caused by birth control pills.

Birth control pills will not protect you from sexually transmitted diseases, including HIV and AIDS. Using a condom is the only way to protect yourself from these diseases.


Dienogest and estradiol side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:

  • sudden numbness or weakness, especially on one side of the body;




  • sudden severe headache, confusion, problems with vision, speech, or balance;




  • sudden cough, wheezing, rapid breathing, coughing up blood;




  • pain, swelling, warmth, or redness in one or both legs;




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;




  • jaundice (yellowing of the skin or eyes);




  • a change in the pattern or severity of migraine headaches;




  • swelling in your hands, ankles, or feet;




  • a breast lump; or




  • symptoms of depression (sleep problems, weakness, mood changes).



Less serious side effects may include:



  • mild nausea or vomiting, appetite or weight changes;




  • breast swelling or tenderness;




  • headache, nervousness, dizziness;




  • problems with contact lenses;




  • freckles or darkening of facial skin, loss of scalp hair; or




  • vaginal itching or discharge.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Dienogest and estradiol Dosing Information


Usual Adult Dose for Contraception:

One tablet taken orally, once a day, consecutively in the order directed on the package for 28 days with the next pack to be started the day after the last pack.

Dienogest-estradiol products are packaged in 28 day dosage preparations.

The cycle length for oral contraceptives is generally considered to be 28 days. (The first day of menstrual bleeding is counted as day 1).

Initiation of Oral Contraceptive Therapy:

This product can be started one of the following ways:

1. No preceding hormonal contraceptive use in the past month: Start on day 1 of the woman's natural cycle;

2. For postpartum women who do not breastfeed or after a second trimester abortion: Start on day 28 after delivery or abortion. The patient should be advised to use additional barrier methods for the first 9 days of tablet taking. However, if intercourse has already taken place, pregnancy should be excluded before use or the patient should wait until the first menstrual cycle.

3. Changing from a combined oral contraceptive, vaginal ring, or transdermal patch: Instruct her to take the first dark yellow pill on the first day of her withdrawal bleed. She should not continue taking the pills from her previous birth control pack. If she does not have a withdrawal bleed, rule out pregnancy before starting dienogest-estradiol. If she previously used a vaginal ring or transdermal patch, she should start using dienogest-estradiol on the day the ring or patch is removed. Instruct the patient to use a non-hormonal backup method such as a condom or spermicide for the first 9 days.

4. Changing from a progesterone-only method: Instruct her to take the first dark yellow pill on the day she would have taken her next progestin-only pill or on the day of removal of her implant or intrauterine system or on the day when she would have had her next injection. Instruct the patient to use a non-hormonal backup method such as a condom or spermicide for the first 9 days.

Missed Doses:

If a woman is less than 12 hours late for an active tablet, the missed dose should be taken as soon as it is remembered and the normal schedule should be resumed.

If a woman is more than 12 hours late for an active tablet, please follow the following principles:

Day 1 to 17: Take the missed tablet immediately and the rest as usual. Use backup contraception for the next 9 days.
Day 18 to 24: Discard the current cycle, start a new cycle immediately. Use backup contraception for the next 9 days.
Day 25 to 28: Take the missed tablet immediately and following tablets as usual. No backup contraception is required.

If a woman misses TWO PILLS in a row, please follow the following principles:

Days 1-17 (if she misses the pills for Days 17 and 18, follow the instructions for Days 17-25 instead):
Do not take the missed pills. Instead, take the pill for the day on which you first noticed you had missed pills. Use backup contraception for the next 9 days. Continue taking one pill each day at the same time for the rest of the cycle.
Days 17-25 (if she misses the pills for Days 25 and 26, follow the instructions for Days 25-28 instead):
Do not take any pills from the current blister pack and throw the pack away. Take Day 3 pill from a new blister pack. Use backup contraception for the next 9 days. Continue taking one pill from the new blister pack at the same time each day.
Days 25-28:
Do not take any pills from the current blister pack and throw the pack away. Start a new pack on the same day or start a new pack on the day you usually start a new pack. No backup contraception is needed. Continue taking one pill from the new pack at the same time each day, for the rest of the cycle.


What other drugs will affect dienogest and estradiol?


Many drugs can make birth control pills less effective, which may result in pregnancy. Below is just a partial list:



  • antifungal medication (Sporanox, Extina, Ketozole, Nizoral, Vfend, and others);




  • certain antibiotics (especially Biaxin, Ery-Tab, Erythrocin, Ketek, and others);




  • certain antidepressants, or St. John's wort;




  • certain HIV medications;




  • certain seizure medications;




  • St. John's wort;




  • isoniazid (for treating tuberculosis);




  • rifabutin (Mycobutin), rifampin (Rifadin, Rifater, Rifamate), or rifapentine (Priftin);




  • thyroid replacement (Synthroid, Levothroid, and others);




  • phenobarbital or other barbiturates; or




  • heart or blood pressure medication (especially Cartia, Cardizem, Cardene, Procardia, Calan, Covera, Isoptin, Verelan, and others).



This list is not complete and other drugs may interact with dienogest and estradiol. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More dienogest and estradiol resources


  • Dienogest and estradiol Dosage
  • Dienogest and estradiol Use in Pregnancy & Breastfeeding
  • Dienogest and estradiol Drug Interactions
  • Dienogest and estradiol Support Group
  • 9 Reviews for Dienogest and estradiol - Add your own review/rating


Compare dienogest and estradiol with other medications


  • Birth Control


Where can I get more information?


  • Your pharmacist can provide more information about dienogest and estradiol.


Saturday, 22 May 2010

Ansaid


Ansaid is a brand name of flurbiprofen, approved by the FDA in the following formulation(s):


ANSAID (flurbiprofen - tablet; oral)



  • Manufacturer: PHARMACIA AND UPJOHN

    Approval date: October 31, 1988

    Strength(s): 100MG [RLD][AB], 50MG [AB]

Has a generic version of Ansaid been approved?


Yes. The following products are equivalent to Ansaid:


flurbiprofen tablet; oral



  • Manufacturer: CARACO

    Approval date: April 27, 2001

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: June 20, 1994

    Strength(s): 100MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: May 31, 1995

    Strength(s): 100MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ansaid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ansaid.

See also...

  • Ansaid Consumer Information (Wolters Kluwer)
  • Ansaid Consumer Information (Cerner Multum)
  • Ansaid Advanced Consumer Information (Micromedex)
  • Ansaid AHFS DI Monographs (ASHP)
  • Flurbiprofen Consumer Information (Wolters Kluwer)
  • Flurbiprofen Consumer Information (Cerner Multum)
  • Flurbiprofen Advanced Consumer Information (Micromedex)
  • Flurbiprofen AHFS DI Monographs (ASHP)

Monday, 17 May 2010

Desloratadine


Class: Second Generation Antihistamines
ATC Class: R06AX27
VA Class: AH109
Chemical Name: 8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
Molecular Formula: C19H19ClN2
CAS Number: 100643-71-8
Brands: Clarinex, Clarinex-D 24-Hour

Introduction

Second generation antihistamine; active descarboethoxy metabolite of loratadine.1 2 3 9


Uses for Desloratadine


Allergic Rhinitis


Symptomatic relief of nasal and nonnasal symptoms of perennial allergic rhinitis.1


Symptomatic relief (alone or in fixed combination with pseudoephedrine sulfate) of nasal and nonnasal symptoms of seasonal (e.g., hay fever) allergic rhinitis.1 9 18 19 Use fixed-combination preparation only when both antihistamine and nasal decongestant activity are desired.18


Improves nasal and nonnasal symptoms in patients with seasonal allergic rhinitis and concomitant mild to moderate asthma without impairing pulmonary function.1 2 6 9


Chronic Idiopathic Urticaria


Symptomatic treatment of pruritus and urticaria associated with chronic idiopathic urticaria.1


Desloratadine Dosage and Administration


Administration


Oral Administration


Administer conventional tablets, oral solution, orally disintegrating tablets, and fixed-combination extended-release tablets orally once daily without regard to meals.1 9 18


Orally disintegrating tablets: Remove tablet from blister just prior to administration.1 Place tablet on the tongue, allow it to disintegrate, then swallow with or without water.1


Oral solution: To measure and administer dose, use a dropper or syringe calibrated to deliver 2 or 2.5 mL.1


Fixed-combination desloratadine/pseudoephedrine sulfate extended-release tablets: Swallow whole; do not chew, break, or crush.18


Dosage


Fixed-combination preparation contains 5 mg of desloratadine in an immediate-release outer shell and 240 mg of pseudoephedrine sulfate in an extended-release matrix core that slowly releases the drug.18


Pediatric Patients


Allergic Rhinitis

Seasonal

Oral

Children 2–5 years of age: 1.25 mg once daily (as oral solution).1


Children 6–11 years of age: 2.5 mg once daily (as oral solution or orally disintegrating tablets).1


Children ≥12 years of age: 5 mg once daily (as conventional tablets, oral solution, orally disintegrating tablets, or fixed-combination extended-release tablets with 240 mg pseudoephedrine sulfate).1 18


Perennial

Oral

Children 6–11 months of age: 1 mg once daily (as oral solution).1


Children 1–5 years of age: 1.25 mg once daily (as oral solution).1


Children 6–11 years of age: 2.5 mg once daily (as oral solution or orally disintegrating tablets).1


Children ≥12 years of age: 5 mg once daily (as conventional tablets, oral solution, or orally disintegrating tablets).1


Chronic Idiopathic Urticaria

Oral

Children 6–11 months of age: 1 mg once daily (as oral solution).1


Children 1–5 years of age: 1.25 mg once daily (as oral solution).1


Children 6–11 years of age: 2.5 mg once daily (as oral solution or orally disintegrating tablets).1


Children ≥12 years of age: 5 mg once daily (as conventional tablets, oral solution, or orally disintegrating tablets).1


Adults


Allergic Rhinitis

Seasonal

Oral

5 mg once daily (as conventional tablets, oral solution, orally disintegrating tablets, or fixed-combination extended-release tablets with pseudoephedrine sulfate).1 18


Perennial

Oral

5 mg once daily (as conventional tablets, oral solution, or orally disintegrating tablets).1


Chronic Idiopathic Urticaria

Oral

5 mg once daily (as conventional tablets, oral solution, or orally disintegrating tablets).1 9


Prescribing Limits


Pediatric Patients


Allergic Rhinitis

Oral

Children ≥12 years of age: Dosages >5 mg provide no additional benefit but may increase risk of adverse effects (e.g., somnolence).1 9


Adults


Allergic Rhinitis

Oral

Dosages >5 mg provide no additional benefit but may increase risk of adverse effects (e.g., somnolence).1 9


Special Populations


Dosage adjustment based on gender, race, or age generally not necessary.1 3


Hepatic Impairment


Pediatric patients: No specific dosage recommendations at this time because of lack of data.1


Adults: 5 mg every other day (as conventional tablets, oral solution, or orally disintegrating tablets).1 Avoid fixed-combination preparation.18


Renal Impairment


Pediatric patients: No specific dosage recommendations at this time because of lack of data.1


Adults: 5 mg every other day (as conventional tablets, oral solution, orally disintegrating tablets, or fixed-combination tablets).1 18


Cautions for Desloratadine


Contraindications



  • Known hypersensitivity to desloratadine, loratadine, or any ingredient in the formulation.1



Warnings/Precautions


General Precautions


Shares the toxic potentials of loratadine and other second generation antihistamines; observe usual precautions related to therapy with such drugs.1


Use of Fixed Combination

When using fixed-combination preparation containing pseudoephedrine sulfate, consider the cautions, precautions, and contraindications associated with pseudoephedrine.18


Phenylketonuria

Clarinex RediTabs contain aspartame (NutraSweet), which is metabolized in the GI tract to provide 1.4 or 2.9 mg of phenylalanine per 2.5- or 5-mg tablet, respectively.1


Specific Populations


Pregnancy

Category C.1


Lactation

Distributed into milk.1 18 Discontinue nursing or the drug.1 18 Caution if fixed-combination preparation is used in nursing women.18


Pediatric Use

Safety and efficacy not established for seasonal allergic rhinitis in children <2 years of age.1


Safety and efficacy not established for perennial allergic rhinitis or chronic idiopathic urticaria in children <6 months of age.1


Safety and efficacy of fixed combination for seasonal allergic rhinitis not established in children <12 years of age.18


Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.22 23 Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.22 Therefore, FDA recommended not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns. Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 18 Select dosage with caution.1 18 (See Elimination: Special Populations, under Pharmacokinetics.)


Hepatic Impairment

Conventional tablets, oral solution, or orally disintegrating tablets: Dosage reduction recommended.1 (See Hepatic Impairment under Dosage and Administration and also see Elimination: Special Populations, under Pharmacokinetics.)


Fixed-combination desloratadine/pseudoephedrine sulfate preparation: Use not recommended.18


Renal Impairment

Conventional tablets, oral solution, or orally disintegrating tablets: Dosage reduction recommended.1 (See Renal Impairment under Dosage and Administration and also see Absorption: Special Populations, under Pharmacokinetics.)


Fixed-combination desloratadine/pseudoephedrine sulfate preparation: Dosage reduction recommended.18 (See Renal Impairment under Dosage and Administration.)


Common Adverse Effects


Children 6–11 months of age receiving oral solution: Upper respiratory tract infection, diarrhea, fever, irritability, coughing, somnolence, bronchitis, otitis media, vomiting.1


Children 12–23 months of age receiving oral solution: Fever, diarrhea, upper respiratory tract infection, coughing.1


Children 2–5 years of age receiving oral solution: Fever.1


Adults and children ≥12 years of age receiving conventional or orally disintegrating tablets for management of allergic rhinitis: Pharyngitis,1 3 4 9 dry mouth.1 3 4 9


Adults and children ≥12 years of age receiving conventional or orally disintegrating tablets for management of chronic idiopathic urticaria: Headache,1 7 9 nausea,1 fatigue.1 7


Fixed-combination desloratadine/pseudoephedrine sulfate preparation: Dry mouth, headache, insomnia.18


Interactions for Desloratadine


No formal drug interaction studies conducted with fixed-combination desloratadine/pseudoephedrine sulfate preparation.18 When using this preparation, consider drug interactions associated with pseudoephedrine (e.g., MAO inhibitors).18


Drugs Affecting Hepatic Microsomal Enzymes


Potential pharmacokinetic interaction (increased plasma concentrations of desloratadine and active metabolite) with drugs affecting hepatic microsomal enzymes.1 9 (See Specific Drugs and Foods under Interactions.)


Specific Drugs and Foods

















Drug or Food



Interaction



Azithromycin



Increased plasma concentrations of desloratadine and active metabolite;1 9 no clinically important changes in ECG or laboratory evaluations, vital signs, or adverse effects1 9



Cimetidine



Increased plasma concentrations of desloratadine and active metabolite;1 9 no clinically important changes in ECG or laboratory evaluations, vital signs, or adverse effects1 9



Erythromycin



Increased plasma concentrations of desloratadine and active metabolite;1 9 no clinically important changes in ECG or laboratory evaluations, vital signs, or adverse effects1 9



Fluoxetine



Increased plasma concentrations of desloratadine and active metabolite;1 9 no clinically important changes in ECG or laboratory evaluations, vital signs, or adverse effects1 9



Grapefruit juice



Pharmacokinetic interaction unlikely1 3



Ketoconazole



Increased plasma concentrations of desloratadine and active metabolite;1 9 no clinically important changes in ECG or laboratory evaluations, vital signs, or adverse effects1 9


Desloratadine Pharmacokinetics


Absorption


Bioavailability


Conventional tablets and oral solution are bioequivalent.1 Reformulated orally disintegrating tablets are bioequivalent to the original orally disintegrating formulation (no longer commercially available);1 original formulation previously shown to be bioequivalent to conventional tablets and oral solution.20


Peak plasma concentrations occur at approximately 3 or 6–7 hours following administration of conventional tablets or fixed-combination extended-release preparation, respectively.1 18


Onset


Following single- and multiple-dose administration, antihistaminic effects occur within 1 hour.1 Symptomatic (nasal and nonnasal) improvement observed as early as 1 day after initiation of therapy.2 4 5 6 9


Duration


Following single- and multiple-dose administration, antihistaminic effects persist for up to 24 hours.1 No evidence of histamine-induced skin wheal tachyphylaxis over 28-day treatment period.1


Food


Food or grapefruit juice does not appear to affect bioavailability following administration as conventional tablets, oral solution,1 or fixed-combination tablets;18 water does not appear to affect bioavailability following administration as orally disintegrating tablets.1


Special Populations


In patients with renal impairment and those who require hemodialysis, peak plasma desloratadine concentrations and AUC are increased.1


Distribution


Plasma Protein Binding


Approximately 82–87% (for desloratadine) and 85–89% (for 3-hydroxydesloratadine).1


Special Populations

Protein binding not altered in patients with renal impairment.1


Elimination


Metabolism


Extensively metabolized to 3-hydroxydesloratadine (active metabolite), which subsequently undergoes glucuronidation; enzyme(s) responsible for metabolism of desloratadine not identified.1


Elimination Route


Approximately 87% excreted as metabolic products in urine and feces in equal proportions.1


Desloratadine and 3-hydroxydesloratadine are poorly removed by hemodialysis.1


Half-life


27 hours for desloratadine and 3-hydroxydesloratadine.1


Special Populations


Approximately 6% of patients are poor metabolizers (decreased ability to form 3-hydroxydesloratadine); higher frequency of poor metabolizers in blacks (17%) than in Caucasians (2%) or Hispanics (2%).1 18 Substantially (approximately 6-fold) greater drug exposure in poor metabolizers than in normal metabolizers;1 however, no overall differences in safety observed between these groups.1 18 Nevertheless, an increased risk of adverse effects in poor metabolizers cannot be ruled out.1 18


In patients ≥65 years of age, plasma desloratadine concentrations are increased and elimination half-life is prolonged.1


In patients with hepatic impairment, AUC and elimination half-life are increased and clearance is decreased.1


Stability


Storage


Oral


Tablets and Orally Disintegrating Tablets

25°C (may be exposed to 15–30°C).1


Solution

25°C (may be exposed to 15–30°C).1 Protect from light.1


Fixed-combination Tablets

25°C (may be exposed to 15–30°C).18 Protect from excessive moisture.18


ActionsActions



  • Specific, selective peripheral H1-receptor antagonist;1 2 3 4 6 9 relatively “nonsedating” or second generation antihistamine.2 5 6 7 9




  • May suppress release of histamine from human mast cells.1 9




  • May reduce nasal congestion/stuffiness.2 3 5 9



Advice to Patients



  • Importance of adhering to prescribed dosage regimen and directions for use; increase in dosage or dosing frequency not recommended since higher dosages provide no additional benefit but may increase risk of adverse effects (e.g., somnolence).1




  • Importance of informing patients with phenylketonuria that orally disintegrating tablets contain aspartame.1




  • Importance of avoiding concomitant use of fixed-combination preparation with OTC antihistamines and/or decongestants.18




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.1




  • Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.




























Desloratadine

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Solution



0.5 mg/mL



Clarinex Syrup



Schering



Tablets, film-coated



5 mg



Clarinex



Schering



Tablets, orally disintegrating



2.5 mg



Clarinex RediTabs



Schering



5 mg



Clarinex RediTabs



Schering













Desloratadine Combinations

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, extended-release core (pseudoephedrine sulfate only)



5 mg with Pseudoephedrine Sulfate 240 mg



Clarinex-D 24-Hour



Schering


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Clarinex 0.5MG/ML Syrup (SCHERING): 473/$222.98 or 1419/$638.98


Clarinex 5MG Tablets (SCHERING): 30/$140.99 or 90/$396.96


Clarinex Reditabs 2.5MG Dispersible Tablets (SCHERING): 30/$155.99 or 90/$421.99


Clarinex Reditabs 5MG Dispersible Tablets (SCHERING): 30/$145.99 or 90/$411.99


Clarinex-D 12 Hour 2.5-120MG 12-hr Tablets (SCHERING): 100/$312.99 or 300/$870.95


Clarinex-D 24 Hour 5-240MG 24-hr Tablets (SCHERING): 30/$145.99 or 90/$426.95



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Schering Corporation. Clarinex (desloratadine) tablets, syrup, RediTabs tablets prescribing information. Kenilworth, NJ; 2005 Apr.



2. McClellan K and Jarvis B. Desloratadine. Drugs. 2001; 61:789-96. [PubMed 11398910]



3. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001; 10:547-60. [PubMed 11424898]



4. Meltzer EO, Prenner BM, Nayak A for the Desloratadine Study Group. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy seasons. Clin Drug Invest. 2001; 21:25-32.



5. Nayak AS and Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001; 56:1077-80. [PubMed 11703222]



6. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy. 2001; 56(Suppl):21-7. [PubMed 11243501]



7. Ring J, Hein R, Gauger A et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001; 40:1-5. [PubMed 11277944]



8. Gupta S, Banfield C, Kantesaria B et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 2001; 23:451-66. [IDIS 465266] [PubMed 11318079]



9. Schering, Kenilworth, NJ: Personal communication.



10. Borge PA. Problems in allergic rhinitis. Arzneimittelforschung. 1982; 32:1199-201. [PubMed 6891258]



11. Anon. Treatment of seasonal and perennial rhinitis. BMJ. 1981; 283:808-10. [PubMed 6117350]



12. Food and Drug Administration. Over-the-counter drugs: establishment of a monograph for OTC cold, cough, allergy, bronchodilator and antiasthmatic products. [21 CFR 341] Fed Regist. 1976; 41:38312-424. (IDIS 66640)



13. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacologic basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:605-38.



14. Cirillo VJ, Tempero KF. The pharmacology and therapeutic use of H1 and H2 antihistamines. In: Miller RR, Greenblatt DJ, eds. Drug therapy reviews. Vol 2. New York: Elsevier/North Holland Inc; 1979:24-47.



15. Church JA. Allergic rhinitis: diagnosis and management. Clin Pediatr (Philadelphia). 1980; 19:655-9.



16. AMA Division of Drugs. AMA drug evaluations. 5th ed. Chicago: American Medical Association; 1983:1465-79.



17. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; tentative final monograph for OTC antihistamine drug products. [21 FR Part 341] Fed Regist. 1985; 50:2200-18. (IDIS 195256)



18. Schering Corporation. Clarinex-D 24-Hour (desloratadine 5 mg and pseudoephedrine sulfate) extended-release tablets prescribing information. Kenilworth, NJ; 2005 Mar.



19. Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005; 94:348-54. [PubMed 15801245]



20. Schering Corporation. Clarinex (desloratadine) tablets, syrup, RediTabs tablets prescribing information. Kenilworth, NJ; 2004 Aug.



21. Schering-Plough. FDA approves re-formulated Clarinex (desloratadine) RediTabs tablets—orally disintegrating prescription antihistamine. Kenilworth, NJ: 2005 Jul 15. Press release. From website ().



22. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. [PubMed 17218934]



23. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website ().



More Desloratadine resources


  • Desloratadine Side Effects (in more detail)
  • Desloratadine Use in Pregnancy & Breastfeeding
  • Desloratadine Drug Interactions
  • Desloratadine Support Group
  • 8 Reviews for Desloratadine - Add your own review/rating


  • Desloratadine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Desloratadine Prescribing Information (FDA)

  • Desloratadine Professional Patient Advice (Wolters Kluwer)

  • desloratadine Advanced Consumer (Micromedex) - Includes Dosage Information

  • Clarinex Consumer Overview

  • Clarinex Prescribing Information (FDA)

  • Clarinex Reditabs Orally Disintegrating Tablets MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Desloratadine with other medications


  • Hay Fever
  • Urticaria

Sunday, 16 May 2010

Retterspitz Darmreinigungspulver




Retterspitz Darmreinigungspulver may be available in the countries listed below.


Ingredient matches for Retterspitz Darmreinigungspulver



Magnesium Sulfate

Magnesium Sulfate heptahydrate (a derivative of Magnesium Sulfate) is reported as an ingredient of Retterspitz Darmreinigungspulver in the following countries:


  • Germany

International Drug Name Search

Monday, 10 May 2010

Denosumab


Pronunciation: den-OH-sue-mab
Generic Name: Denosumab
Brand Name: Xgeva


Denosumab is used for:

Preventing certain bone-related events in patients who have a certain type of tumor that has spread to the bones (bone metastases).


Denosumab is a receptor activator of nuclear factor-kappa B (RANK) ligand inhibitor. It works by decreasing the formation, function, and survival of certain bone cells (osteoclasts) that are responsible for slowing bone loss. Decreased osteoclast activity helps to reduce the risk of bone-related events in patients with cancer that has spread to the bone.


Do NOT use Denosumab if:


  • you are allergic to any ingredient in Denosumab

  • you have multiple myeloma

Contact your doctor or health care provider right away if any of these apply to you.



Before using Denosumab:


Some medical conditions may interact with Denosumab. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of kidney problems or you are on dialysis

  • if you have low blood calcium levels, cannot take daily calcium or vitamin D supplements, or plan to have dental surgery or teeth removed

Some MEDICINES MAY INTERACT with Denosumab. However, no specific interactions with Denosumab are known at this time.


Ask your health care provider if Denosumab may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Denosumab:


Use Denosumab as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Denosumab is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Denosumab at home, a health care provider will teach you how to use it. Be sure you understand how to use Denosumab. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.

  • Use the proper technique taught to you by your doctor. Inject deep under the skin, NOT into a vein or muscle.

  • Denosumab is a colorless to pale yellow solution that may contain a very small amount of clear to white particles. Do not use Denosumab if it contains many particles or any foreign matter. Do not use it if the solution is cloudy or discolored, or if the vial is cracked or damaged.

  • Do not vigorously shake Denosumab.

  • Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.

  • If you miss a dose of Denosumab, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Denosumab.



Important safety information:


  • Talk to your doctor about taking a calcium or vitamin D supplement while you use Denosumab.

  • Tell your doctor or dentist that you take Denosumab before you receive any medical or dental care, emergency care, or surgery.

  • Denosumab may cause jaw bone problems in some patients. Your risk may be greater if you have had a tooth removed, or a history of poor dental hygiene or use of a dental appliance. Your risk may also be greater if you have had certain dental procedures. Talk to your doctor about having a dental exam before you start to use Denosumab. Ask your doctor any questions you may have about dental treatment while you use Denosumab.

  • Proper dental care is important while you are taking Denosumab. Brush and floss your teeth and visit the dentist regularly.

  • If you have dental surgery while you are using Denosumab, contact your doctor if you have persistent pain or slow healing of the mouth or jaw after the surgery.

  • Lab tests and medical exams, including blood calcium levels and dental exams, may be performed while you use Denosumab. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Denosumab should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed. Denosumab may affect bone growth and tooth development in children.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Denosumab while you are pregnant. It is not known if Denosumab is found in breast milk. Do not breast-feed while taking Denosumab.


Possible side effects of Denosumab:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; headache; nausea; tiredness; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); cough; pain, numbness, swelling, or drainage from the jaw, mouth, or teeth; shortness of breath; symptoms of low blood calcium levels (eg, muscle spasms, twitches, or cramps; burning, numbness, or tingling in your fingers, toes, or around your mouth); symptoms of low blood phosphate levels (eg, new or worsening loss of appetite, muscle weakness or pain, seizures); ulcers of the gums.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Denosumab side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Denosumab:

Denosumab is usually handled and stored by a health care provider. If you are using Denosumab at home, store Denosumab as directed by your pharmacist or health care provider. Keep Denosumab out of the reach of children and away from pets.


General information:


  • If you have any questions about Denosumab, please talk with your doctor, pharmacist, or other health care provider.

  • Denosumab is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Denosumab. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Denosumab resources


  • Denosumab Side Effects (in more detail)
  • Denosumab Use in Pregnancy & Breastfeeding
  • Denosumab Drug Interactions
  • Denosumab Support Group
  • 0 Reviews for Denosumab - Add your own review/rating


Compare Denosumab with other medications


  • Hypercalcemia of Malignancy
  • Osteolytic Bone Metastases of Solid Tumors
  • Osteoporosis

Biperideno




Biperideno may be available in the countries listed below.


Ingredient matches for Biperideno



Biperiden

Biperiden is reported as an ingredient of Biperideno in the following countries:


  • Peru

International Drug Name Search

Tuesday, 4 May 2010

Toviaz


Toviaz is a brand name of fesoterodine, approved by the FDA in the following formulation(s):


TOVIAZ (fesoterodine fumarate - tablet, extended release; oral)



  • Manufacturer: PFIZER

    Approval date: October 31, 2008

    Strength(s): 4MG, 8MG [RLD]

Has a generic version of Toviaz been approved?


No. There is currently no therapeutically equivalent version of Toviaz available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Toviaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Stable salts of novel derivatives of 3,3-diphenylpropylamines
    Patent 6,858,650
    Issued: February 22, 2005
    Inventor(s): Meese; Claus
    Assignee(s): Schwarz Pharma AG
    The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(−)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
    Patent expiration dates:

    • May 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
      ✓ 
      Drug substance




  • Derivatives of 3,3-diphenylpropylamines
    Patent 7,384,980
    Issued: June 10, 2008
    Inventor(s): Meese; Claus & Sparf; Bengt
    Assignee(s): Schwarz Pharma AG
    The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Patent expiration dates:

    • May 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Pharmaceutical compositions comprising fesoterodine
    Patent 7,807,715
    Issued: October 5, 2010
    Inventor(s): Arth; Christoph & Komenda; Michael & Bicane; Fatima & Mika; Hans-Jurgen
    Assignee(s): UCB Pharma GmbH
    The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Patent expiration dates:

    • June 7, 2027
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
      ✓ 
      Drug product




  • Derivatives of 3,3-diphenylpropylamines
    Patent 7,855,230
    Issued: December 21, 2010
    Inventor(s): Meese; Claus & Sparf; Bengt
    Assignee(s): UCB Pharma GmbH
    The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Patent expiration dates:

    • May 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY




  • Derivatives of 3,3-diphenylpropylamines
    Patent 7,985,772
    Issued: July 26, 2011
    Inventor(s): Meese; Claus & Sparf; Bengt
    Assignee(s): UCB Pharma GmbH
    The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Patent expiration dates:

    • May 11, 2019
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Pharmaceutical compositions comprising fesoterodine
    Patent 8,088,398
    Issued: January 3, 2012
    Inventor(s): Mika; Hans-J&#xfc;rgen & Arth; Christoph & Komenda; Michael & Bicane; Fatima
    Assignee(s): UCB Pharma GmbH
    The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Patent expiration dates:

    • June 7, 2027
      ✓ 
      Patent use: TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 31, 2013 - NEW CHEMICAL ENTITY

See also...

  • Toviaz Consumer Information (Drugs.com)
  • Toviaz Consumer Information (Wolters Kluwer)
  • Toviaz Consumer Information (Cerner Multum)
  • Toviaz Advanced Consumer Information (Micromedex)
  • Toviaz AHFS DI Monographs (ASHP)
  • Fesoterodine Consumer Information (Wolters Kluwer)
  • Fesoterodine Consumer Information (Cerner Multum)
  • Fesoterodine Advanced Consumer Information (Micromedex)
  • Fesoterodine Fumarate AHFS DI Monographs (ASHP)